يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Pablo D Perez-Moreno"', وقت الاستعلام: 0.86s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

    المؤلفون: Jinming Yu, Andrés Cardona, Andrea Ardizzoni, Delvys Rodriguez-Abreu, Sergio Azevedo, Belen Rubio-Viqueira, Jorge Alatorre-Alexander, Hans J M Smit, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Pablo D Perez-Moreno

    المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

    مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: https://jitc.bmj.com/content/9/3/e001865.full; https://doaj.org/toc/2051-1426

    URL الوصول: https://doaj.org/article/ff460346035746668e4d5b72630465b6

    Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer

    المؤلفون: Peter Schmid, Charles E. Geyer Jr, Nadia Harbeck, Mothaffar Rimawi, Sara Hurvitz, Miguel Martín, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil L. Stroyakovsky, Vanesa López-Valverde, Michael Davis, Tanja Badovinac Crnjevic, Pablo D. Perez-Moreno, Aditya Bardia

    المصدر: Cancer Research. 83:OT2-03

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c6344357bb4da14feeb88c001c0db158
    https://doi.org/10.1158/1538-7445.sabcs22-ot2-03-02

    أضف إلى المفضلة
  3. 3
    Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer

    المؤلفون: Elgene Lim, Marianna Chavez, Aditya Bardia, Joo Hyuk Sohn, Heather M. Moore, Mahesh Shivhare, Jorge Martinalbo, Laura Roncoroni, Pablo D. Perez-Moreno, Miguel Martín

    المصدر: Cancer Research. 83:PD13-04

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9cca937a9296a138c41c789af9fcfda1
    https://doi.org/10.1158/1538-7445.sabcs22-pd13-04

    أضف إلى المفضلة
  4. 4
    Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

    المؤلفون: Jorge Arturo Alatorre-Alexander, Hina Patel, Kerstin Trunzer, Delvys Rodriguez-Abreu, Jinming Yu, T. Newsom-Davis, Andrea Ardizzoni, Konstantinos N. Syrigos, A. Cardona, Pablo D Perez-Moreno, Jonathan Tolson, Sergio J. Azevedo, Hans J.M. Smit, Belen Rubio-Viqueira

    المساهمون: Ardizzoni A., Azevedo S., Rubio-Viqueira B., Rodriguez-Abreu D., Alatorre-Alexander J., Smit H.J.M., Yu J., Syrigos K., Trunzer K., Patel H., Tolson J., Cardona A., Perez-Moreno P.D., Newsom-Davis T.

    المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
    Journal for Immunotherapy of Cancer

    مصطلحات موضوعية: Male, Cancer Research, Lung Neoplasms, Time Factors, medicine.medical_treatment, B7-H1 Antigen, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Immunology and Allergy, Medicine, Prospective Studies, 030212 general & internal medicine, subgroup analysis, Immune Checkpoint Inhibitors, PD-L1 inhibitor, phase IIII clinical trial, RC254-282, Clinical/Translational Cancer Immunotherapy, Aged, 80 and over, education.field_of_study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, clinical trial, Middle Aged, Progression-Free Survival, metastatic, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Molecular Medicine, Female, immunotherapy, Human, Adult, medicine.medical_specialty, Time Factor, Immune Checkpoint Inhibitor, Immunology, Population, Subgroup analysis, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, Atezolizumab, Internal medicine, Humans, Lung cancer, Adverse effect, education, Aged, Neoplasm Staging, Pharmacology, clinical trials, Chemotherapy, business.industry, medicine.disease, lung neoplasm, Clinical trial, Prospective Studie, checkpoint inhibitor, subgroup analysi, business

    وصف الملف: ELETTRONICO

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eab59190df89e0778b3830277629745
    https://jitc.bmj.com/content/9/3/e001865.full

    Find this article in full text from ProQuest
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء